The Types axis of market taxonomy distinguishes pyrazinamide products by manufacturing form and branding, primarily encompassing generic active pharmaceutical ingredient (API), branded finished‑dose formulations, and dosage‑form variations such as tablets, capsules, and injectable solutions. Generic API supplies dominate the cost‑driven bulk segment, representing roughly 60 % of total volume, because emerging economies rely on low‑price raw material imports for national TB programs. Branded finished‑dose products, accounting for about 30 % of sales, command higher margins through patented formulations, enhanced stability, and compliance‑focused packaging, which are preferred in high‑income markets with stringent regulatory oversight. Dosage‑form differentiation adds a further 10 % split between solid oral tablets (≈7 %) and parenteral injectables (≈3 %); tablets remain the standard for first‑line therapy, while injectables are reserved for patients with severe gastrointestinal intolerance or for use in pediatric and hospital settings. By quantifying each type’s share, analysts can trace pricing dynamics, supply‑chain resilience, and the impact of regulatory pathways on the overall Pyrazinamide market.
